Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials

Interim analysis of the Phase I and II trials of an inactivated whole-virus COVID-19 vaccine candidate developed in Wuhan reports it demonstrated immunogenicity and a low rate of adverse reactions; longer-term assessment of safety and efficacy will require phase 3 trials.


Journal of the American Medical Association